Global epidemiology of tuberculosis

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 2, 2015, Pages

  Glaziou, Philippe ^a   Sismanidis, Charalambos ^a   Floyd, Katherine ^a   Raviglione, Mario ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CAUSE OF DEATH; CHEMOTHERAPY; CHILDHOOD DISEASE; DRUG SENSITIVITY; EPIDEMIOLOGICAL MONITORING; HIV ASSOCIATED TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; PREVENTION AND CONTROL; TREATMENT OUTCOME; TUBERCULOSIS; COMPLICATION; COST OF ILLNESS; INFECTION CONTROL; WORLD HEALTH ORGANIZATION;

COMMUNICABLE DISEASE CONTROL; COST OF ILLNESS; HIV INFECTIONS; HUMANS; INCIDENCE; PREVALENCE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 84923772103     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a017798     Document Type: Article

References (104)

1. Ambe G, Lonnroth K, Dholakia Y, Copreaux J, Zignol M, Borremans N, Uplekar M. 2005. Every provider counts: Effect of a comprehensive public-private mix approach for TB control in a large metropolitan area in India. Int J Tuberc Lung Dis 9: 562-568.
2. Baussano I, Bugiani M, Gregori D, van Hest R, Borraccino A, Raso R, Merletti F. 2006. Undetected burden of tubercu-losis in a low-prevalence area. Int J Tuberc Lung Dis 10: 415-421.
3. Bierrenbach AL, Stevens AP, Gomes AB, Noronha EF, Glatt R, Carvalho CN, Oliveira Junior JG, Souza Mde F. 2007. [Impact on tuberculosis incidence rates of removal of repeat notification records]. Revista de saude publica 41: 67-76.
4. Bock NN, Jensen PA, Miller B, Nardell E. 2007. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 196: S108-S113.
5. Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. 2000. Gender and tuberculosis: A comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis 4: 123-132.
6. Borgdorff MW, Glynn JR, Vynnycky E. 2004. Using capture-recapture methods to study recent transmission of tuber-culosis. Int J Epidemiol 33: 905-906.
7. Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. 2011. The incubation period distri-bution of tuberculosis estimated with a molecular epide-miological approach. Int J Epidemiol 40: 964-970.
8. Botha E, den Boon S, Lawrence KA, Reuter H, Verver S, Lombard CJ, Dye C, Enarson DA, Beyers N. 2008. From suspect to patient: Tuberculosis diagnosis and treatment initiation in health facilities in South Africa. Int J Tuberc Lung Dis 12: 936-941.
9. Cailhol J, Che D, Jarlier V, Decludt B, Robert J. 2005. Inci-dence of tuberculous meningitis in France, 2000: A capture-recapture analysis. Int J Tuberc Lung Dis 9: 803-808.
10. Churchyard GJ, Scano F, Grant AD, Chaisson RE. 2007. Tuberculosis preventive therapy in the era of HIV infection: Overview and research priorities. J Infect Dis 196: S52-S62.
11. Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, et al. 2013. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet 45: 1176-1182.
12. Connolly M, Nunn P. 1996. Women and tuberculosis. World Health Stat Q 49: 115-119.
13. Corbett EL, Charalambous S, Moloi VM, Fielding K, Grant AD, Dye C, De Cock KM, Hayes RJ, Williams BG, Churchyard GJ. 2004. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 170: 673-679.
14. Crofts JP, Pebody R, Grant A, Watson JM, Abubakar I. 2008. Estimating tuberculosis case mortality in England and Wales, 2001-2002. Int J Tuberc Lung Dis 12: 308-313.
15. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, et al. 2012. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin com-binations: A randomised trial. Lancet 380: 986-993.
16. Dye C, Floyd K. 2006. Tuberculosis. In Disease Control Priorities Priorities in Developing Countries (ed. Jamison DT et al.), pp. 289-309. Oxford University Press, Washington, DC.
17. Dye C, Raviglione M. 2013. Weigh all TB risks. Nature 502: S13.
18. Dye C, Williams BG. 2008. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5: 653-662.
19. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. 1999. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282: 677-686.
20. Dye C, Fengzeng Z, Scheele S, Williams B. 2000. Evaluating the impact of tuberculosis control: Number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol 29: 558-564.
21. Dye C, Ottmani S, Laasri L, Bencheikh N. 2007. The decline of tuberculosis epidemics under chemotherapy: A case study in Morocco. Int J Tuberc Lung Dis 11: 1225-1231.
22. Dye C, Bassili A, Bierrenbach AL, Broekmans JF, Chadha VK, Glaziou P, Gopi PG, Hosseini M, Kim SJ, Manissero D, et al. 2008. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 8: 233-243.
23. Dye C, Glaziou P, Floyd K, Raviglione M. 2013. Prospects for tuberculosis elimination. Annu Rev Public Health 34: 271-286.
24. Enarson DA, Grzybowski S. 1986. Incidence of active tuber-culosis in the native population of Canada. CMAJ 134: 1149-1152.
25. Floyd K, Arora VK, Murthy KJ, Lonnroth K, Singla N, Akbar Y, Zignol M, Uplekar M. 2006. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: Evidence from India. Bull World Health Organ 84: 437-445.
26. Glaziou P, van der Werf MJ, Onozaki I, Dye C, Borgdorff MW, Chiang CY, Cobelens F, Enarson DA, Gopi PG, Holtz TH, et al. 2008. Tuberculosis prevalence surveys: Rationale and cost. Int J Tuberc Lung Dis 12: 1003-1008.
27. Glaziou P, Floyd K, Korenromp EL, Sismanidis C, Bierren-bach AL, Williams BG, Atun R, Raviglione M. 2011. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ 89: 573-582.
28. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cab-rera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, et al. 2012. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366: 2151-2160.
29. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. 2005. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS (London, England) 19: 163-168.
30. Grzybowski S, Styblo K, Dorken E. 1976. Tuberculosis in Eskimos. Tubercle 57: S1-S58.
31. Harries AD, Zachariah R, Lawn SD. 2009. Providing HIV care for co-infected tuberculosis patients: A perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 13: 6-16.
32. Holloway KL, Henneberg RJ, de Barros Lopes M, Henneberg M. 2011. Evolution of human tuberculosis: A systematic review and meta-analysis of paleopathological evidence. Homo 62: 402-458.
33. Hong YP, KSJ, Lew WJ, Lee EK, Han YC. 1998. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 2: 27-36.
34. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. 2006. International standards for tuberculosis care. Lan-cet Infect Dis 6: 710-725.
35. Korenromp EL, Williams BG, Dye C. 2009. The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis 13: 283-303.
36. Korenromp EL, Glaziou P, Fitzpatrick C, Floyd K, Hosseini M, Raviglione M, Atun R, Williams B. 2012. Implementing the global plan to stop TB, 2011-2015—Optimizing allocations and the Global Fund’s contribution: A scenario projections study. PLoS ONE 7: e38816.
37. Lienhardt C, Glaziou P, Uplekar M, Lonnroth K, Getahun H, Raviglione M. 2012a. Global tuberculosis control: Lessons learnt and future prospects. Nat Rev Microbiol 10: 407-416.
38. Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jara-millo E, Hoelscher M, Zumla A, Gheuens J. 2012b. New drugs for the treatment of tuberculosis: Needs, challenges, promise, and prospects for the future. J Infect Dis 205: S241-S249.
39. Lonnroth K, Raviglione M. 2008. Global epidemiology of tuberculosis: Prospects for control. Semin Respir Crit Care Med 29: 481-491.
40. Lonnroth K, Uplekar M. 2005. Invest in breaking the barriers of public-private collaboration for improved tuberculosis care. Bull World Health Organ 83: 558-559.
41. Lonnroth K, Uplekar M, Arora VK, Juvekar S, Lan NT, Mwaniki D, Pathania V. 2004. Public-private mix for DOTS implementation: What makes it work? Bull World Health Organ 82: 580-586.
42. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. 2009. Drivers of tuberculosis epidemics: The role of risk factors and social determinants. Soc Sci Med 68: 2240-2246.
43. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC. 2010. Tuberculosis control and elimination 2010-50: Cure, care, and social development. Lancet 375: 1814-1829.
44. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. 2006. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 367: 1747-1757.
45. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095-2128.
46. Ly LH, McMurray DN. 2008. Tuberculosis: Vaccines in the pipeline. Expert Rev Vaccines 7: 635-650.
47. Manissero D, Fernandez de la Hoz K. 2006. Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: Summary update. Euro Surveill 11: E061103.1.
48. Meintjes G, Schoeman H, Morroni C, Wilson D, Maartens G. 2008. Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: A cross-sectional study. BMC Infect Dis 8: 72.
49. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. 2007a. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 12: E070517.1.
50. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 2007b. 125 years after Robert Koch’s discovery of the tubercle bacillus: The new XDR-TB threat. Is “science” enough to tackle the epidemic? Eur Respir J 29: 423-427.
51. Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. 1996. Isoniazid-related fatal hepatitis. West J Med 164: 486-491.
52. Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE. 2009. Personal and societal health quality lost to tuberculosis. PLoS ONE 4: e5080.
53. Moreno-Serra R, Smith PC. 2012. Does progress towards universal health coverage improve population health? Lancet 380: 917-923.
54. Murray CJ, DeJonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. 1991. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 338: 1305-1308.
55. Nicolau I, Ling D, Tian L, Lienhardt C, Pai M. 2012. Research questions and priorities for tuberculosis: A survey of published systematic reviews and meta-analyses. PLoS ONE 7: e42479.
56. O’Neill K, Takane M, Sheffel A, Abou-Zahr C, Boerma T. 2013. Monitoring service delivery for universal health coverage: The Service Availability and Readiness Assess-ment. Bull World Health Organ 91: 923-931.
57. Ortblad KF, Lozano R, Murray CJ. 2013. The burden of HIV: Insights from the Global Burden of Disease Study 2010. AIDS 27: 2003-2017.
58. Ottmani SE, Uplekar MW. 2008. Gender and TB: Pointers from routine records and reports. Int J Tuberc Lung Dis 12: 827-828.
59. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezen-beek CS, Kim SJ, Chaulet P, et al. 1998. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 338: 1641-1649.
60. Pai M, O’Brien R. 2008. New diagnostics for latent and active tuberculosis: State of the art and future prospects. Semin Respir Crit Care Med 29: 560-568.
61. Pantoja A, Floyd K, Unnikrishnan KP, Jitendra R, Padma MR, Lal SS, Uplekar M, Chauhan LS, Kumar P, Sahu S, et al. 2009. Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis 13: 698-704.
62. Raviglione M. 2006a. XDR-TB: Entering the post-antibiotic era? Int J Tuberc Lung Dis 10: 1185-1187.
63. Raviglione MC. 2006b. The Global Plan to Stop TB, 2006-2015. Int J Tuberc Lung Dis 10: 238-239.
64. Raviglione MC. 2007. The new Stop TB Strategy and the Global Plan to Stop TB, 2006-2015. Bull World Health Organ 85: 327.
65. Raviglione MC, Pio A. 2002. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 359: 775-780.
66. Raviglione MC, Smith IM. 2007. XDR tuberculosis-Implications for global public health. N Engl J Med 356: 656-659.
67. Raviglione MC, Uplekar MW. 2006. WHO’s new Stop TB Strategy. Lancet 367: 952-955.
68. Raviglione M, Marais B, Floyd K, Lonnroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, et al. 2012a. Scaling up interventions to achieve global tuberculosis control: Progress and new developments. Lancet 379: 1902-1913.
69. Raviglione M, Zumla A, Marais B, Horton R, Motsoaledi A. 2012b. A sustainable agenda for tuberculosis control and research. Lancet 379: 1077-1078.
70. Riley RL. 1983. The contagiosity of tuberculosis. Schweiz Med Wochenschr 113: 75-79.
71. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martin-Casabona N, Drobniewski F, Gilpin C, Havelkova M, Lepe R, et al. 2007. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13: 380-387.
72. Shilova MV, Dye C. 2001. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond B Biol Sci 356: 1069-1075.
73. Soemantri S, Senewe FP, Tjandrarini DH, Day R, Basri C, Manissero D, Mehta F, Dye C. 2007. Three-fold reduction in the prevalence of tuberculosis over 25 years in Indonesia. Int J Tuberc Lung Dis 11: 398-404.
74. Somma D, Thomas BE, Karim F, Kemp J, Arias N, Auer C, Gosoniu GD, Abouihia A, Weiss MG. 2008. Gender and socio-cultural determinants of TB-related stigma in Bangladesh, India, Malawi and Colombia. Int J Tuberc Lung Dis 12: 856-866.
75. Squire SB, Obasi A, Nhlema-Simwaka B. 2006. The Global Plan to Stop TB: A unique opportunity to address poverty and the Millennium Development Goals. Lancet 367: 955-957.
76. Sterling TR. 2008. New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med 29: 532-541.
77. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, et al. 2011. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365: 2155-2166.
78. Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. 2010. The effect of tuberculosis on mortality in HIV positive people: A meta-analysis. PLoS ONE 5: e15241.
79. Straetemans M, Glaziou P, Bierrenbach AL, Sismanidis C, van der Werf MJ. 2011. Assessing tuberculosis case fatal-ity ratio: A meta-analysis. PLoS ONE 6: e20755.
80. Styblo K, Meijer J, Sutherland I. 1969. [The transmission of tubercle bacilli: Its trend in a human population]. Bull World Health Organ 41: 137-178.
81. Thorson A, Long NH, Larsson LO. 2007. Chest X-ray findings in relation to gender and symptoms: A study of patients with smear positive tuberculosis in Vietnam. Scand J Infect Dis 39: 33-37.
82. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. 2011. Natural history of tuberculosis: Duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PLoS ONE 6: e17601.
83. Tupasi TE, Radhakrishna S, Rivera AB, Pascual MLG, Quel-apio MI, Co VM, Villa MLA, Beltran G, Legaspi JD, Mangubat NV, et al. 1999. The 1997 nationwide tuberculosis prevalence survey in the Philippines. Int J Tuberc Lung Dis 3: 471-477.
84. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. 2012. Totally drug-resistant tuberculosis in India. Clin Infect Dis 54: 579-581.
85. Uplekar M, Pathania V, Raviglione M. 2001. Private practitioners and public health: Weak links in tuberculosis control. Lancet 358: 912-916.
86. Van Hest N, Story A, Grant AD, Antoine D, Crofts JP, Wat-son JM. 2008. Record-linkage and capture-recapture analysis to estimate the incidence and completeness of reporting of tuberculosis in England 1999-2002. Epide-miol Infect 136: 1606-1616.
87. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: Super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136: 420-425.
88. Veron LJ, Blanc LJ, Suchi M, Raviglione MC. 2004. DOTS expansion: Will we reach the 2005 targets? Int J Tuberc Lung Dis 8: 139-146.
89. Vynnycky E, Fine PE. 2000. Lifetime risks, incubation peri-od, and serial interval of tuberculosis. Am J Epidemiol 152: 247-263.
90. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. 2007. HIV infection and multidrug-resistant tuberculosis: The perfect storm. J Infect Dis 196: S86-S107.
91. Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D’Am-brosio L, Zignol M, Floyd K, Centis R, Cirillo DM, Tortoli E, et al. 2013. Rapid molecular TB diagnosis: Evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 42: 252-271.
92. WHO. 2006. WHO Global Task Force outlines measures to combat XDR-TB worldwide [Internet]. WHO, Geneva.
93. WHO. 2011a. The Global Plan to Stop TB 2011-2015.
94. WHO. 2011b. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drugresistant tuberculosis by 2015. WHO progress report 2011. (ed. WHO). WHO, Geneva.
95. WHO ed. 2011c. Tuberculosis prevalence surveys: A handbook. World Health Organization, Geneva.
96. WHO. 2012a. Health financing for universal coverage. WHO, Geneva.
97. WHO. 2012b. Tuberculosis fact sheet. WHO, Geneva.
98. WHO. 2013a. Global TB report 2013 WHO, Geneva.
99. WHO. 2013b. Roadmap for childhood tuberculosis. (ed. WHO). WHO, Geneva.
100. Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C. 2010. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci 107: 19485-19489.
101. Woldehanna S, Volmink J. 2004. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane database of systematic reviews (Online): CD000171.
102. World Health Organization. 2007. Global tuberculosis control: Surveillance, planning, financing. World Health Organization, Geneva.
103. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M. 2012. Surveillance of anti tuberculosis drug resistance in the world: An updated analysis, 2007-2010. Bull World Health Organ 90: 111-119D.
104. Zumla A, Mwaba P, Huggett J, Kapata N, Chanda D, Grange J. 2009. Reflections on the white plague. Lancet Infect Dis 9: 197-202.